Christmas T I, Manning L S, Garlepp M J, Musk A W, Robinson B W
Department of Medicine, University of Western Australia, Nedlands.
J Interferon Res. 1993 Feb;13(1):9-12. doi: 10.1089/jir.1993.13.9.
Malignant mesothelioma (MM) is a tumor that is resistant to conventional therapy. Interferon-alpha (IFN-alpha) has been used in the treatment of some human tumors, and we have previously demonstrated an in vitro anti-proliferative effect of IFN against MM cell lines. Therefore, the effect of recombinant human IFN-alpha (IFN-alpha 2a) (Roferon-A, Hoffmann-La Roche) on previously untreated patients with MM has been studied. Twenty-five patients (24 male and 1 female), with a mean age of 59 +/- 9.9 years, were treated for 3 months with IFN-alpha 2a. The starting dose was 3 x 10(6) IU daily increasing to a maximum of 18 x 10(6) IU daily or as tolerated. All patients had measurable tumor on thoracic CT prior to commencement. CT scans were performed at 6 and 12 weeks to determine tumor response. Twenty patients completed 3 months of treatment. Five patients were withdrawn because of disease progression. Side effects were predictable and dose related. Dose reductions were necessary in 12 patients for grade 2 toxicity. One patient had a complete response (CR), 2 patients had partial responses (PR) (response rate = 12%), 13 (52%) patients remained stable, 1 of whom exhibited a delayed PR, and 9 (36%) had progressive disease. These data suggest that IFN-alpha 2a is well tolerated in patients with MM and is active against MM in a proportion of patients.
恶性间皮瘤（MM）是一种对传统疗法耐药的肿瘤。α干扰素（IFN-α）已被用于治疗某些人类肿瘤，并且我们之前已经证明IFN对MM细胞系具有体外抗增殖作用。因此，我们研究了重组人α干扰素（IFN-α 2a）（罗扰素，霍夫曼-罗氏公司）对既往未经治疗的MM患者的疗效。25例患者（24例男性和1例女性），平均年龄59±9.9岁，接受IFN-α 2a治疗3个月。起始剂量为每日3×10⁶国际单位，最大增至每日18×10⁶国际单位或根据耐受情况调整。所有患者在开始治疗前胸部CT检查均有可测量的肿瘤。在第6周和12周进行CT扫描以确定肿瘤反应。20例患者完成了3个月的治疗。5例患者因疾病进展而退出。副作用是可预测的且与剂量相关。12例患者因2级毒性需要减少剂量。1例患者完全缓解（CR），2例患者部分缓解（PR）（缓解率=12%），13例（52%）患者病情稳定，其中1例出现延迟PR，9例（36%）病情进展。这些数据表明，MM患者对IFN-α 2a耐受性良好，且一部分患者对MM有活性。
